3-[(3-(2-Carboxyethyl)-4-methylpyrrol-2-YL)methylene]-2-indolinone


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
11116 CEP43 Decreases activity PMID:16103074
1848 DUSP6 Decreases expression PMID:15255957
2246 FGF1 Decreases expression PMID:12421715
2247 FGF2 Affects expression PMID:12421715
2248 FGF3 Decreases expression PMID:12421715
2252 FGF7 Increases expression PMID:12421715
2255 FGF10 Increases expression PMID:12421715
2260 FGFR1 Decreases activity PMID:12421715; PMID:16091734; PMID:16154193; PMID:16188231; PMID:16103074
2260 FGFR1 Increases expression PMID:12421715
2261 FGFR3 Affects expression PMID:14871245
2261 FGFR3 Decreases activity PMID:15029211; PMID:16091734
26281 FGF20 Decreases activity PMID:12704805
51176 LEF1 Decreases expression PMID:15255957
5594 MAPK1 Decreases expression PMID:14871245
5595 MAPK3 Decreases expression PMID:14871245
652 BMP4 Increases expression PMID:12421715
655 BMP7 Decreases expression PMID:12421715
6774 STAT3 Decreases expression PMID:14871245
6869 TACR1 Decreases expression PMID:16154193
6926 TBX3 Decreases expression PMID:15255957
79923 NANOG Increases expression PMID:19937756
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.